Johnson & Johnson Reports Q2 2022 Results
New Brunswick, N.J. (July 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2022. “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, Chief Executive Officer. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.”OVERALL FINANCIAL RESULTS
expand
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items Note: values may have been roundedREGIONAL SALES RESULTS
expand
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: Values may have been roundedSEGMENT SALES RESULTS
expand
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures in...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Financial Source Type: news
More News: Arthritis | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | China Health | Chronic Leukemia | Chronic Lymphocytic Leukemia | Conferences | Covid Vaccine | COVID-19 | Environmental Health | Government | Grants | Health Management | Heart | Imodium | Invega | Invega Sustenna | Legislation | Leukemia | Loperamide | Medical Ethics | Myeloma | Oral Cancer | Outbreaks | Pandemics | Pharmaceuticals | Podcasts | Profits and Losses | Prostate Cancer | Psoriasis | Psoriatic Arthritis | Remicade | Respiratory Medicine | Rheumatology | SARS | Schizophrenia | Science | Skin | Stelara | Strategic Planning | Vaccines | Websites